Ramya Antony

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

J. Doroshow, A. Chen, E. Polley, 2015, Investigational New Drugs.

The prevalence of altered body image in patients with primary brain tumors: an understudied population

M. Gilbert, K. Camphausen, T. Mendoza, 2020, Journal of Neuro-Oncology.

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

M. Gilbert, T. Mendoza, Ying Yuan, 2021, Clinical Cancer Research.

Report of Canonical BCR-ABL1 Fusion in Glioblastoma.

K. Zaghloul, Jun S. Wei, M. Gilbert, 2021, JCO Precision Oncology.